Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 62946

Monday, 07/07/2008 3:19:59 AM

Monday, July 07, 2008 3:19:59 AM

Post# of 257580
MNTA: Teva’s phase-3 trial of the 40mg dose of Copaxone in MS failed to show any benefit vs the standard 20mg dose:

http://www.reuters.com/article/marketsNews/idINBNG13619120080707

This is modestly good news for MNTA in that Teva’s US patents on the 40mg dose might have harder to overturn or circumvent than the patents on the standard 20mg dose. (MNTA is developing a generic version of Copaxone with its partner, NVS.)



Let’s talk biotech!
What if there were no hypothetical questions?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today